If breast cancer is diagnosed at an early stage, it has a higher chance of being cured. Therefore, it is important that you ...

The following highlights showcase the most pivotal, innovative research published across multiple therapeutic areas in ...

HER2-positive (HER2+) breast cancer treatments come with a range of unpleasant side effects. However, there are strategies ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

Medically reviewed by Archana Sharma, DO Eating well can help support your immune system and maintain strength and energy if ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

Trastuzumab Emtansine Improves Long-Term Survival in HER2 ... cancer has identified two inhibitor drugs with the potential to interrupt disease ... Feb. 3, 2025 — Psoriasis is a chronic skin ...

Jan. 15, 2025 — In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive ...